Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | August 12, 2026 | August 14, 2026 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Chief Financial Officer | May 08, 2026 | May 12, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Chief Financial Officer | November 18, 2024 | November 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,981 |
Ending reported balance
After 2026-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 6,138 · Balance 11,119 Row 2 · 2026-08-12 · Sale · Disposed 7,138 · Balance 3,981 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.56 · Expires 2032-06-29 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 6,138 · Balance 0 F2: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
Odyssey Therapeutics, Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,908 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Purchase · Acquired 1,000 · Balance 62,908 |
Syros Pharmaceuticals, Inc.
Report date November 18, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-18 transaction · row 1
1 source rowRow 1 · 2024-11-18 · Sale · Disposed 137,803 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 21:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,138 | $0.00 Strike: $51.56 | $0.00 |
DisclosureSEC source: 0002001011-26-000114 · edgardoc.xml · derivative · entry 3 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,138 shares Expires 2032-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 7,138 | $292.81 | $2,090,062.08 |
DisclosureSEC source: 0002001011-26-000114 · edgardoc.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,981 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 6,138 | $51.56 | $316,475.28 |
DisclosureSEC source: 0002001011-26-000114 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $51.56 | $0.00 |
DisclosureSEC source: 0002001011-26-000104 · edgardoc.xml · derivative · entry 6 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,138 Underlying: Common Stock · 1,000 shares Expires 2032-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $51.56 | $0.00 |
DisclosureSEC source: 0002001011-26-000104 · edgardoc.xml · derivative · entry 5 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,138 Underlying: Common Stock · 3,000 shares Expires 2032-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,461 | $256.08 | $886,286.30 |
DisclosureSEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 4 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,981 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $256.0000 to $256.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,000 | $255.01 | $765,033.90 |
DisclosureSEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 3 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,442 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $255.0000 to $255.2900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,000 | $51.56 | $51,560.00 |
DisclosureSEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,000 | $51.56 | $154,680.00 |
DisclosureSEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,938 | $0.00 Strike: $237.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000097 · edgardoc.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,938 Underlying: Common Stock · 2,938 shares Expires 2036-06-05 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 836 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000097 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,442 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 08, 2026 Filed May 12, 2026 00:32 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | PurchaseCommon Stock | 1,000 | $20.00 | $20,000.00 |
DisclosureSEC source: 0001193125-26-217600 · ownership.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,908 Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,783 | $0.00 Strike: $105.99 | $0.00 |
DisclosureSEC source: 0002001011-25-000040 · edgardoc.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 5,783 shares Expires 2035-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,209 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000040 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,606 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 17:00 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 137,803 | $0.21 | $28,979.97 |
DisclosureSEC source: 0000950170-24-129378 · ownership.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 17:01 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 18,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-120869 · ownership.xml · derivative · entry 3 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 17:01 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Tax withholdingCommon Stock | 5,624 | $2.09 | $11,754.16 |
DisclosureSEC source: 0000950170-24-120869 · ownership.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,803 F2 · kind: Represents shares used to cover tax withholding on a restricted stock unit release. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 17:01 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 18,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-120869 · ownership.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 17:00 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 45,344 | $1.68 | $76,005.61 |
DisclosureSEC source: 0000950170-24-105995 · ownership.xml · nonDerivative · entry 3 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,552 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 17:00 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 19,293 | $1.58 | $30,446.28 |
DisclosureSEC source: 0000950170-24-105995 · ownership.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,208 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 17:00 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 35,363 | $1.55 | $54,787.90 |
DisclosureSEC source: 0000950170-24-105995 · ownership.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,915 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,444 | $0.00 Strike: $80.06 | $0.00 |
DisclosureSEC source: 0002001011-24-000057 · edgardoc.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 5,444 shares Expires 2034-06-14 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000057 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,397 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Tax withholdingCommon Stock | 4,732 | $5.12 | $24,227.84 |
DisclosureSEC source: 0000950170-24-040289 · ownership.xml · nonDerivative · entry 3 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,552 F2 · kind: Represents shares used to cover tax withholding upon the release of restricted stock units. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040289 · ownership.xml · derivative · entry 5 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040289 · ownership.xml · derivative · entry 4 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-040289 · ownership.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-040289 · ownership.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 16:53 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Tax withholdingCommon Stock | 6,301 | $2.22 | $13,988.22 |
DisclosureSEC source: 0001209191-23-054172 · doc4.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,951 F2 · kind: Represents shares used to cover tax withholding on a restricted stock unit release. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 16:53 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 18,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054172 · doc4.xml · derivative · entry 3 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,875 Underlying: Common Stock · 18,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 16:53 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 18,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054172 · doc4.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:53 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,461 | $0.00 Strike: $73.76 | $0.00 |
DisclosureSEC source: 0000886163-23-000039 · edgardoc.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,461 Underlying: Common Stock · 5,461 shares Expires 2033-06-09 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:53 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-23-000039 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,145 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 18:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Tax withholdingCommon Stock | 623 | $2.58 | $1,607.34 |
DisclosureSEC source: 0001209191-23-022979 · doc4.xml · nonDerivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,377 F3 · kind: Represents shares used to cover tax withholding on a restricted stock unit release. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022979 · doc4.xml · derivative · entry 3 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. F2 · balance_after: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-022979 · doc4.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. F2 · balance_after: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 16:21 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011162 · doc4.xml · derivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter. F2 · derivative.expiration_date: These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 16:37 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantRestricted Stock Units · Derivative | 37,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053316 · doc4.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,750 Underlying: Common Stock · 37,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. F3 · derivative.expiration_date: These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 16:37 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 49,750 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001209191-22-053316 · doc4.xml · derivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,750 Underlying: Common Stock · 49,750 shares Expires 2032-10-05 F1 · derivative.exercise_date: This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,907 | $0.00 Strike: $88.48 | $0.00 |
DisclosureSEC source: 0000886163-22-000103 · edgardoc.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,907 Underlying: Common Stock · 5,907 shares Expires 2032-06-29 F1 · derivative.exercise_date: The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000103 · edgardoc.xml · nonDerivative · entry 1 Haas Jason · CIK 0001883821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:07 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantRestricted Stock Units · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010707 · doc4.xml · derivative · entry 2 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: These RSUs will vest in four equal annual installments commencing on March 31, 2023. F3 · derivative.expiration_date: These RSUs will vest in four equal annual installments commencing on March 31, 2023. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:07 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-22-010707 · doc4.xml · derivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 16:06 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001209191-21-060358 · doc4.xml · derivative · entry 1 Haas Jason · CIK 0001883821 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-10-11 F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on October 12, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.